Results 281 to 290 of about 483,027 (406)

Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high‐grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in preclinical models

open access: yes
Cancer Communications, EarlyView.
Monika Raab   +10 more
wiley   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

open access: yesEuropean Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo   +22 more
wiley   +1 more source

Peptide RL‐QN15 Regulates Functions of Epidermal Stem Cells to Accelerate Skin Wound Regeneration via the FZD8/β‐Catenin Axis

open access: yesExploration, EarlyView.
Amphibian‐derived peptide RL‐QN15 activates the Wnt/β‐catenin signaling pathway by interacting with the FZD8 membrane receptor, promoting epidermal stem cells proliferation, migration, stemness, and EMT processes, thus promoting skin wound healing.
Yuansheng Li   +15 more
wiley   +1 more source

Rme1, a negative regulator of meiosis, is also a positive activator of G1 cyclin gene expression. [PDF]

open access: bronze, 1995
W. Mark Toone   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy